Rona Therapeutics and Keymed Biosciences Announce Collaboration to Discover and Develop First-in-class siRNA Therapeutics for Glomerulonephritis

SHANGHAI,May 15,2023 -- Rona Therapeutics,Inc ("Rona") and Keymed Biosciences ("Keymed",HKEX: 02162),today announced a collaboration to jointly discover and develop first-in-class siRNA therapeutics for Glomerulonephritis (also referred as severe kidney diseases). The collaboration will leverage both companies' scientific and technological expertise and will build on Rona's proprietary platform in RNAi targeting liver and extrahepatic tissues.

Under the term of the collaboration,Rona will use proprietary RAZOR™ platform to discover and identify siRNA lead compounds directed to a novel target related to glomerulonephritis and Keymed will contribute research and translational expertise and capabilities. Keymed and Rona have entered into a profit/loss arrangement to further co-develop and commercialize therapeutic product candidates globally that emerge from these discovery efforts. The program is expected to enter into clinical stage in the first half of 2024.

"We are looking forward to partnering with Keymed to jointly discover and develop transformative RNA therapeutics globally," said Stella SHI,the founder and CEO of Rona. "Rona's proprietary next generation siRNA platform technology and the advanced biology expertise from Keymed is a strategic fit for developing first-in-class siRNA therapeutic for devastating diseases like glomerulonephritis."

"I am delightful to announcethiscollaboration between Keymed and Rona," said Dr. Bo CHEN,the founder and CEO of Keymed. "We keep focusing on the urgent unmet clinical needs and dedicating to provide patients with high-quality,affordable,and innovative therapies. Taking advantage of Rona's pioneering next generation siRNA platform and Keymed's sophisticated biology expertise,the collaboration will provide exciting opportunities for both companies to explore the potential targets that have not been successfully modulated through conventional therapeutic modalities."

Glomerulonephritis is a prominent cause of renal impairment and constitutes 25% to 30% of all end-stage renal disease cases. Common forms of primary glomerulonephritis include IgA Nephropathy (global prevalence is ~2.5 case per 100,000 persons,with much higher prevalence in Asia),Lupus nephritis (prevalence is 8-180 cases per 100,000 persons),Membranous nephropathy (incidence of 8-10 cases per 1 million persons),etc. There is an urgent need for new medicines that treat glomerulonephritis,as there are currently fewapproved drugs for the disease.

About Rona Therapeutics

Rona Therapeutics is a pioneering RNA therapeutics platform company dedicated to discovery and development of modular and programmable RNA medicines to deliver to patients around the world.

Backed by blue-chip investors,Rona has developed proprietary RAZOR™ platform to discover differentiated siRNA therapeutics from next-generation chemical modification and novel biological insights. Together with partners,Rona is dedicated to advancing transformative RNA therapeutics into clinic in metabolic syndrome,glomerulonephritis,CNS and ocular diseases. www.ronatherapeutics.com.

About Keymed Biosciences

Keymed Biosciences is a biotechnology company focused on the in house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. We have established a fully integrated platform encompassing all the key functions in the biologic drug development,which enabled us to rapidly and cost-effectively identify,build,expand and advance our diversified pipeline. www.keymedbio.com.